Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

steris plc (ireland) - STE

STE

Close Chg Chg %
260.75 2.08 0.80%

Open Market

262.83

+2.08 (0.80%)

Volume: 194.99K

Last Updated:

Dec 5, 2025, 1:38 PM EDT

Trade Now

Company Overview: steris plc (ireland) - STE

STE Key Data

Open

$262.60

 Day Range

260.10 - 263.99

52 Week Range

200.98 - 268.60

 Market Cap

$25.62B

Shares Outstanding

98.15M

 Public Float

97.82M

Beta

1.01

 Rev. Per Employee

N/A

P/E Ratio

36.92

 EPS

$7.06

Yield

92.52%

 Dividend

$0.63

EX-DIVIDEND DATE

Nov 18, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

742.81K

  

STE Performance

1 Week
 
 -1.98%
 
1 Month
 
 -1.04%
 
3 Months
 
 6.41%
 
1 Year
 
 20.90%
 
5 Years
 
 34.90%
 

STE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About steris plc (ireland) - STE

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

STE At a Glance

STERIS Plc (Ireland)
70 Sir John Rogerson's Quay
Dublin, Dublin 2
Phone N/A Revenue 5.46B
Industry Medical Specialties Net Income 628.64M
Sector Health Technology 2025 Sales Growth 6.243%
Fiscal Year-end 03 / 2026 Employees 17,787
View SEC Filings

STE Valuation

P/E Current 36.923
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 35.719
Price to Sales Ratio 4.113
Price to Book Ratio 3.374
Price to Cash Flow Ratio 19.60
Enterprise Value to EBITDA 16.748
Enterprise Value to Sales 4.487
Total Debt to Enterprise Value 0.09

STE Efficiency

Revenue/Employee 306,938.494
Income Per Employee 35,342.441
Receivables Turnover 5.23
Total Asset Turnover 0.515

STE Liquidity

Current Ratio 1.957
Quick Ratio 1.389
Cash Ratio 0.168

STE Profitability

Gross Margin 44.312
Operating Margin 18.069
Pretax Margin 14.584
Net Margin 11.515
Return on Assets 5.753
Return on Equity 9.455
Return on Total Capital 6.929
Return on Invested Capital 6.699

STE Capital Structure

Total Debt to Total Equity 33.355
Total Debt to Total Capital 25.012
Total Debt to Total Assets 21.707
Long-Term Debt to Equity 30.944
Long-Term Debt to Total Capital 23.204
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Steris Plc (ireland) - STE

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
4.59B 4.96B 5.14B 5.46B
Sales Growth
+47.55% +8.13% +3.65% +6.24%
Cost of Goods Sold (COGS) incl D&A
2.57B 2.79B 2.90B 3.04B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
553.10M 552.90M 565.24M 476.21M
Depreciation
184.41M 173.15M 296.93M 200.02M
Amortization of Intangibles
368.70M 379.75M 268.32M 276.19M
COGS Growth
+45.73% +8.63% +3.80% +4.82%
Gross Income
2.01B 2.16B 2.24B 2.42B
Gross Income Growth
+49.93% +7.50% +3.46% +8.09%
Gross Profit Margin
+43.89% +43.63% +43.55% +44.31%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.39B 1.38B 1.33B 1.43B
Research & Development
87.94M 101.58M 103.68M 107.65M
Other SG&A
1.30B 1.28B 1.23B 1.33B
SGA Growth
+89.37% -0.49% -3.86% +7.70%
Other Operating Expense
- - - -
-
Unusual Expense
224.07M 512.58M 69.79M 118.96M
EBIT after Unusual Expense
397.91M 267.08M 838.05M 867.55M
Non Operating Income/Expense
6.18M (1.74M) 9.11M 14.92M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
89.59M 107.99M 144.35M 86.26M
Interest Expense Growth
+140.97% +20.53% +33.67% -40.24%
Gross Interest Expense
93.48M 114.36M 151.44M 93.42M
Interest Capitalized
3.89M 6.37M 7.09M 7.16M
Pretax Income
314.50M 157.35M 702.81M 796.21M
Pretax Income Growth
-39.23% -49.97% +346.66% +13.29%
Pretax Margin
+6.86% +3.17% +13.68% +14.58%
Income Tax
71.63M 51.53M 149.53M 184.65M
Income Tax - Current - Domestic
174.95M 171.44M 159.73M 177.54M
Income Tax - Current - Foreign
- 70.28M 58.92M 64.17M
Income Tax - Deferred - Domestic
(103.32M) (165.05M) (54.71M) (48.13M)
Income Tax - Deferred - Foreign
- (25.14M) (14.41M) (8.92M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
242.87M 105.81M 553.28M 611.56M
Minority Interest Expense
(1.02M) (1.22M) 1.84M 1.43M
Net Income
243.89M 107.03M 551.44M 610.12M
Net Income Growth
-38.63% -56.12% +415.22% +10.64%
Net Margin Growth
+5.32% +2.16% +10.73% +11.18%
Extraordinaries & Discontinued Operations
- - (173.20M) 18.51M
-
Discontinued Operations
- - (173.20M) 18.51M
-
Net Income After Extraordinaries
243.89M 107.03M 378.24M 628.64M
Preferred Dividends
- - - -
-
Net Income Available to Common
243.89M 107.03M 378.24M 628.64M
EPS (Basic)
2.5005 1.0735 3.8288 6.3772
EPS (Basic) Growth
-46.39% -57.07% +256.67% +66.56%
Basic Shares Outstanding
97.53M 99.71M 98.79M 98.58M
EPS (Diluted)
2.4804 1.0677 3.8068 6.3454
EPS (Diluted) Growth
-46.39% -56.95% +256.54% +66.69%
Diluted Shares Outstanding
98.33M 100.25M 99.36M 99.07M
EBITDA
1.18B 1.33B 1.47B 1.46B
EBITDA Growth
+42.06% +13.40% +10.55% -0.70%
EBITDA Margin
+25.63% +26.88% +28.67% +26.79%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 288.00
Number of Ratings 10 Current Quarters Estimate 2.53
FY Report Date 12 / 2025 Current Year's Estimate 10.205
Last Quarter’s Earnings 2.47 Median PE on CY Estimate N/A
Year Ago Earnings 9.33 Next Fiscal Year Estimate 11.135
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 8
Mean Estimate 2.53 2.88 10.21 11.14
High Estimates 2.61 2.96 10.25 11.26
Low Estimate 2.47 2.82 10.05 10.75
Coefficient of Variance 1.60 1.69 0.67 1.55

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 3 3 4
UNDERWEIGHT 1 1 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Steris Plc (ireland) - STE

Date Name Shares Transaction Value
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 10,731 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $182.22 per share 1,955,402.82
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 7,407 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $257.43 per share 1,906,784.01
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 7,195 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $258.03 per share 1,856,525.85
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 5,695 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $257.76 per share 1,467,943.20
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Mohsen M. Sohi Director 26,471 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $64.05 per share 1,695,467.55
Aug 13, 2025 Louis A. Shapiro Director 975 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Paul E. Martin Director 4,562 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Mohsen M. Sohi Director 7,750 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director 7,244 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director 2,226 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director 22,361 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $241.96 per share 5,410,467.56
Aug 13, 2025 Cynthia L. Feldmann Director 8,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Cynthia L. Feldmann Director 1,407 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Nirav R. Shah Director 6,503 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Cynthia L. Feldmann Director 4,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Christopher S. Holland Director 4,964 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Richard Carroll Breeden Director 19,545 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Richard Carroll Breeden Director 19,190 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Steris Plc (Ireland) in the News